Business Model Breakdown
How Exicure Inc Makes Money
XCUR
Market Cap
$17M
Profit Margin
-165.8%
Employees
7
The Short Version
Exicure Inc. currently operates as a dormant public shell company. It has no active revenue-generating operations, products, or services. Its prior focus on developing nucleic acid therapies was ceased, and all related assets were liquidated. The company's primary 'business' function is currently to maintain its public listing status, utilizing its remaining cash reserves. Its future, if any, is entirely dependent on a potential reverse merger with an operational private company seeking public market access.
Where the Revenue Comes From
None ($0 revenue reported from Q1 2026 preliminary figures).
Who buys: None (no active business or products).
Why It Works (Competitive Advantages)
- ✔None (no active business to create or sustain advantages).
Economic Moat: None
What Our Analysis Says
DVR Score as of May 24, 2026
Exicure Inc. (XCUR) remains fundamentally unchanged as a dormant shell company with no active operations, clinical pipeline, or discernible business model as of May 2026. The company reports $0 revenue and continues to incur net losses, eroding its critically low cash position of $2.5 million. While still listed on NASDAQ, it faces regulatory risk with a delayed Q1 2026 10-Q filing. The previous EPS 'beat' for Q4 2025 is misleading, reflecting a reduction in estimated operational burn rather than business improvement. There is no clear strategic vision, competitive advantage, or organic catalysts for growth. The only potential for re-rating is highly speculative and unannounced reverse merger possibilities, which are not tied to any fundamental business. The 10x growth potential remains fundamentally absent.